Plasma levels of VIP are not elevated during PACAP- and VIP-induced cluster headache attacks: an exploratory study
BackgroundPituitary adenylate cyclase-activating peptide (PACAP) and vasoactive intestinal peptide (VIP) provoked cluster headache attacks in individuals with episodic cluster headache during their active phase and individuals with chronic cluster headache. In this study, we investigated whether inf...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-04-01
|
| Series: | Frontiers in Neurology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fneur.2023.1135246/full |
| _version_ | 1797844952758091776 |
|---|---|
| author | Christina Deligianni Lanfranco Pellesi Basit Ali Chaudhry Anne Luise Haulund Vollesen Agneta Henriette Snoer Jens Hannibal Rigmor Højland Jensen Messoud Ashina |
| author_facet | Christina Deligianni Lanfranco Pellesi Basit Ali Chaudhry Anne Luise Haulund Vollesen Agneta Henriette Snoer Jens Hannibal Rigmor Højland Jensen Messoud Ashina |
| author_sort | Christina Deligianni |
| collection | DOAJ |
| description | BackgroundPituitary adenylate cyclase-activating peptide (PACAP) and vasoactive intestinal peptide (VIP) provoked cluster headache attacks in individuals with episodic cluster headache during their active phase and individuals with chronic cluster headache. In this study, we investigated whether infusions of PACAP and VIP caused alterations in plasma levels of VIP and their potential contribution to induced cluster headache attacks.MethodsParticipants received either PACAP or VIP infusion for 20 min on 2 separate days with an interval of at least 7 days in between. Blood collection was performed at T0, T20, T30, and T90. Plasma levels of VIP were measured using a validated radioimmunoassay method.ResultsBlood samples were collected from participants with episodic cluster headache in the active phase (eCHA, n = 14), remission (eCHR, n = 15), and from participants with chronic cluster headache (cCH, n = 15). Baseline levels of VIP did not differ among the three groups (p = 0.1161). During PACAP infusion, mixed-effects analysis revealed a significant increase in plasma levels of VIP in eCHA (p = 0.0300) and eCHR (p = 0.0058) but not in cCH (p = 0.2930). We found no difference in the increase of plasma VIP levels between patients who developed PACAP38- or VIP-induced attacks.ConclusionCluster headache attacks induced by PACAP38 or VIP infusion are not associated with changes in plasma levels of VIP. Further studies are needed to investigate the role of VIP and the parasympathetic system in cluster headache.Clinical trial registrationThe parent study is registered at ClinicalTrials.gov (NCT03814226). |
| first_indexed | 2024-04-09T17:31:48Z |
| format | Article |
| id | doaj.art-b56372d38d704f0aa7a531e2908cc4b2 |
| institution | Directory Open Access Journal |
| issn | 1664-2295 |
| language | English |
| last_indexed | 2024-04-09T17:31:48Z |
| publishDate | 2023-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Neurology |
| spelling | doaj.art-b56372d38d704f0aa7a531e2908cc4b22023-04-18T05:25:08ZengFrontiers Media S.A.Frontiers in Neurology1664-22952023-04-011410.3389/fneur.2023.11352461135246Plasma levels of VIP are not elevated during PACAP- and VIP-induced cluster headache attacks: an exploratory studyChristina Deligianni0Lanfranco Pellesi1Basit Ali Chaudhry2Anne Luise Haulund Vollesen3Agneta Henriette Snoer4Jens Hannibal5Rigmor Højland Jensen6Messoud Ashina7Danish Headache Center, Department of Neurology, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, DenmarkDanish Headache Center, Department of Neurology, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, DenmarkDanish Headache Center, Department of Neurology, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, DenmarkDanish Headache Center, Department of Neurology, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, DenmarkDanish Headache Center, Department of Neurology, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, DenmarkDepartment of Clinical Biochemistry, Bispebjerg Frederiksberg Hospital, Faculty of Health Sciences, University of Copenhagen, Copenhagen, DenmarkDanish Headache Center, Department of Neurology, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, DenmarkDanish Headache Center, Department of Neurology, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, DenmarkBackgroundPituitary adenylate cyclase-activating peptide (PACAP) and vasoactive intestinal peptide (VIP) provoked cluster headache attacks in individuals with episodic cluster headache during their active phase and individuals with chronic cluster headache. In this study, we investigated whether infusions of PACAP and VIP caused alterations in plasma levels of VIP and their potential contribution to induced cluster headache attacks.MethodsParticipants received either PACAP or VIP infusion for 20 min on 2 separate days with an interval of at least 7 days in between. Blood collection was performed at T0, T20, T30, and T90. Plasma levels of VIP were measured using a validated radioimmunoassay method.ResultsBlood samples were collected from participants with episodic cluster headache in the active phase (eCHA, n = 14), remission (eCHR, n = 15), and from participants with chronic cluster headache (cCH, n = 15). Baseline levels of VIP did not differ among the three groups (p = 0.1161). During PACAP infusion, mixed-effects analysis revealed a significant increase in plasma levels of VIP in eCHA (p = 0.0300) and eCHR (p = 0.0058) but not in cCH (p = 0.2930). We found no difference in the increase of plasma VIP levels between patients who developed PACAP38- or VIP-induced attacks.ConclusionCluster headache attacks induced by PACAP38 or VIP infusion are not associated with changes in plasma levels of VIP. Further studies are needed to investigate the role of VIP and the parasympathetic system in cluster headache.Clinical trial registrationThe parent study is registered at ClinicalTrials.gov (NCT03814226).https://www.frontiersin.org/articles/10.3389/fneur.2023.1135246/fullcluster headachePACAP38VIPheadachemigrainepain |
| spellingShingle | Christina Deligianni Lanfranco Pellesi Basit Ali Chaudhry Anne Luise Haulund Vollesen Agneta Henriette Snoer Jens Hannibal Rigmor Højland Jensen Messoud Ashina Plasma levels of VIP are not elevated during PACAP- and VIP-induced cluster headache attacks: an exploratory study Frontiers in Neurology cluster headache PACAP38 VIP headache migraine pain |
| title | Plasma levels of VIP are not elevated during PACAP- and VIP-induced cluster headache attacks: an exploratory study |
| title_full | Plasma levels of VIP are not elevated during PACAP- and VIP-induced cluster headache attacks: an exploratory study |
| title_fullStr | Plasma levels of VIP are not elevated during PACAP- and VIP-induced cluster headache attacks: an exploratory study |
| title_full_unstemmed | Plasma levels of VIP are not elevated during PACAP- and VIP-induced cluster headache attacks: an exploratory study |
| title_short | Plasma levels of VIP are not elevated during PACAP- and VIP-induced cluster headache attacks: an exploratory study |
| title_sort | plasma levels of vip are not elevated during pacap and vip induced cluster headache attacks an exploratory study |
| topic | cluster headache PACAP38 VIP headache migraine pain |
| url | https://www.frontiersin.org/articles/10.3389/fneur.2023.1135246/full |
| work_keys_str_mv | AT christinadeligianni plasmalevelsofviparenotelevatedduringpacapandvipinducedclusterheadacheattacksanexploratorystudy AT lanfrancopellesi plasmalevelsofviparenotelevatedduringpacapandvipinducedclusterheadacheattacksanexploratorystudy AT basitalichaudhry plasmalevelsofviparenotelevatedduringpacapandvipinducedclusterheadacheattacksanexploratorystudy AT anneluisehaulundvollesen plasmalevelsofviparenotelevatedduringpacapandvipinducedclusterheadacheattacksanexploratorystudy AT agnetahenriettesnoer plasmalevelsofviparenotelevatedduringpacapandvipinducedclusterheadacheattacksanexploratorystudy AT jenshannibal plasmalevelsofviparenotelevatedduringpacapandvipinducedclusterheadacheattacksanexploratorystudy AT rigmorhøjlandjensen plasmalevelsofviparenotelevatedduringpacapandvipinducedclusterheadacheattacksanexploratorystudy AT messoudashina plasmalevelsofviparenotelevatedduringpacapandvipinducedclusterheadacheattacksanexploratorystudy |